US › Healthcare

Genelux Corporation Common Stock (GNLX)

US · Healthcare · Biotechnology

$2.42-2.42%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-9.5M

EPS

$-0.21

EPS estimate

$-0.20

EPS came in at -0.21 against a street estimate of -0.20 — a miss of 5.0%.

Key statistics

Market cap

$105.0M

Forward P/E

0.0

P/B

7.05

Book value

$0.36

EPS (TTM)

$-0.86

52-week high

$8.54

52-week low

$2.29

50-day MA

$2.59

200-day MA

$2.78

Beta

0.58

Analyst view

Analysts rate Genelux Corporation Common Stock a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $18.83.

Shareholding

Insiders

12.87%

Institutions

31.17%

Largest institutional holders

Fund	Stake
WOODWARD DIVERSIFIED CAPITAL, LLC	5.06%
Vanguard Capital Management, LLC	3.75%
Bleichroeder LP	3.09%
BlackRock Inc	0.98%
Geode Capital Management, LLC	0.98%
CM Management, LLC	0.89%
Bank of America Corp	0.74%
Vanguard Fiduciary Trust Co	0.53%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Genelux Corporation Common Stock — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.